pdf

O’Melveny Represents Keymed Biosciences in Approximate US$400 Million Hong Kong IPO

July 08, 2021

FOR IMMEDIATE RELEASE

HONG KONG—JULY 8, 2021—O’Melveny recently represented Keymed Biosciences Inc. (2162.HK) in its HK$3.1 billion (US$398 million) IPO and listing on the Hong Kong Stock Exchange.  Assuming full exercise of the over-allotment option, the offering size will be approximately HK$3.57 billion (US$458 million).

Founded in 2016 in Chengdu, Keymed Biosciences is a biotechnology company focused on the in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas.  

Morgan Stanley, China International Capital Corporation, and Huatai International acted as joint global coordinators for the IPO. Cornerstone investors in Keymed Biosciences include Temasek, Hillhouse Capital, Invesco, and UBS Asset Management (Singapore), among others.

The O’Melveny team was led by partners Ke Geng and Ke Zhu, with assistance from counsel Wendy Kan and Grace Xu, associates Edward Poon and Wuxiao Liang, and trainee solicitor Cherry Ma.

About O’Melveny

It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at www.omm.com or learn more in our firm at-a-glance, year-end highlights, and on LinkedIn, Twitter, Facebook, Instagram, and YouTube.

Contact:

Christopher Rieck
O’Melveny & Myers LLP
+1 212 326 2218
crieck@omm.com

Chris Schob
O’Melveny & Myers LLP
+86 21 2307 7000
cschob@omm.com